BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37079030)

  • 1. Role of radiomic analysis of [
    Marturano F; Guglielmo P; Bettinelli A; Zattoni F; Novara G; Zorz A; Sepulcri M; Gregianin M; Paiusco M; Evangelista L
    Eur Radiol; 2023 Oct; 33(10):7199-7208. PubMed ID: 37079030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [
    Ferrari C; Mammucci P; Lavelli V; Pisani AR; Nappi AG; Rubini D; Sardaro A; Rubini G
    Tomography; 2022 Nov; 8(6):2709-2722. PubMed ID: 36412685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [
    Oprea-Lager DE; Gontier E; García-Cañamaque L; Gauthé M; Olivier P; Mitjavila M; Tamayo P; Robin P; García Vicente AM; Bouyeure AC; Bailliez A; Rodríguez-Fernández A; Mahmoud SB; Vallejo-Casas JA; Maksud P; Merlin C; Blanc-Durand P; Drouet C; Tissot H; Vierasu I; Vander Borght T; Boos E; Chossat F; Hodolic M; Rousseau C
    Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3439-3451. PubMed ID: 37341747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual time point imaging of staging PSMA PET/CT quantification; spread and radiomic analyses.
    Aksu A; Vural Topuz Ö; Yılmaz G; Çapa Kaya G; Yılmaz B
    Ann Nucl Med; 2022 Mar; 36(3):310-318. PubMed ID: 34988888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
    BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased Prostate Cancer Glucose Metabolism Detected by
    Lavallée E; Bergeron M; Buteau FA; Blouin AC; Duchesnay N; Dujardin T; Tiguert R; Lacombe L; Fradet V; Makao-Nguile M; Fradet Y; Beauregard JM; Pouliot F
    Eur Urol Focus; 2019 Nov; 5(6):998-1006. PubMed ID: 29609897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of PSMA-PET-guided CT-based radiomic signature to predict biochemical recurrence after salvage radiotherapy.
    Spohn SKB; Schmidt-Hegemann NS; Ruf J; Mix M; Benndorf M; Bamberg F; Makowski MR; Kirste S; Rühle A; Nouvel J; Sprave T; Vogel MME; Galitsnaya P; Gschwend JE; Gratzke C; Stief C; Löck S; Zwanenburg A; Trapp C; Bernhardt D; Nekolla SG; Li M; Belka C; Combs SE; Eiber M; Unterrainer L; Unterrainer M; Bartenstein P; Grosu AL; Zamboglou C; Peeken JC
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2537-2547. PubMed ID: 36929180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Prospective Comparison of
    Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
    Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of PET-CT with
    Puche-Sanz I; Triviño-Ibáñez E; Vázquez-Alonso F; Llamas-Elvira JM; Cózar-Olmo JM; Rodríguez-Fernández A
    Actas Urol Esp; 2017 Sep; 41(7):437-444. PubMed ID: 28389027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Machine learning-based analysis of [
    Cysouw MCF; Jansen BHE; van de Brug T; Oprea-Lager DE; Pfaehler E; de Vries BM; van Moorselaar RJA; Hoekstra OS; Vis AN; Boellaard R
    Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):340-349. PubMed ID: 32737518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of
    Mena E; Rowe SP; Shih JH; Lindenberg L; Turkbey B; Fourquet A; Lin FI; Adler S; Eclarinal P; McKinney YL; Citrin DE; Dahut W; Wood BJ; Chang R; Levy E; Merino M; Gorin MA; Pomper MG; Pinto PA; Eary JF; Choyke PL; Pienta KJ
    J Nucl Med; 2022 Aug; 63(8):1184-1190. PubMed ID: 34916246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer.
    Xiang M; Ma TM; Savjani R; Pollom EL; Karnes RJ; Grogan T; Wong JK; Motterle G; Tosoian JJ; Trock BJ; Klein EA; Stish BJ; Dess RT; Spratt DE; Pilar A; Reddy C; Levin-Epstein R; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Huland H; Tran PT; Martin S; Martinez-Monge R; Krauss DJ; Abu-Isa EI; Alam R; Schwen Z; Pisansky TM; Choo CR; Song DY; Greco S; Deville C; McNutt T; DeWeese TL; Ross AE; Ciezki JP; Boutros PC; Nickols NG; Bhat P; Shabsovich D; Juarez JE; Chong N; Kupelian PA; Rettig MB; Zaorsky NG; Berlin A; Tward JD; Davis BJ; Reiter RE; Steinberg ML; Elashoff D; Horwitz EM; Tendulkar RD; Tilki D; Czernin J; Gafita A; Romero T; Calais J; Kishan AU
    JAMA Netw Open; 2021 Dec; 4(12):e2138550. PubMed ID: 34902034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.
    Lenis AT; Pooli A; Lec PM; Sadun TY; Johnson DC; Lebacle C; Fendler WP; Eiber M; Czernin J; Reiter RE; Calais J
    Eur Urol Oncol; 2022 Oct; 5(5):544-552. PubMed ID: 32958451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Machine learning-based radiomics for multiple primary prostate cancer biological characteristics prediction with
    Yao F; Bian S; Zhu D; Yuan Y; Pan K; Pan Z; Feng X; Tang K; Yang Y
    Radiol Med; 2022 Oct; 127(10):1170-1178. PubMed ID: 36018488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How accurate is
    Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
    Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeatability of Quantitative 18F-Fluoromethylcholine PET/CT Studies in Prostate Cancer.
    Oprea-Lager DE; Kramer G; van de Ven PM; van den Eertwegh AJ; van Moorselaar RJ; Schober P; Hoekstra OS; Lammertsma AA; Boellaard R
    J Nucl Med; 2016 May; 57(5):721-7. PubMed ID: 26697964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of
    Beheshti M; Taimen P; Kemppainen J; Jambor I; Müller A; Loidl W; Kähkönen E; Käkelä M; Berndt M; Stephens AW; Minn H; Langsteger W
    Eur Radiol; 2023 Jan; 33(1):472-482. PubMed ID: 35864350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of
    Chevalme YM; Boudali L; Gauthé M; Rousseau C; Skanjeti A; Merlin C; Robin P; Giraudet AL; Janier M; Talbot JN
    Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2935-2950. PubMed ID: 33416958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone Uptake in Prostate Cancer Patients: Diagnostic Performances of PSMA-RADS v1.0, Clinical, Biological, and 68 Ga-PSMA-11 PET Features to Predict Metastasis After Biochemical Recurrence.
    Letang A; Crombé A; Rousseau C; Sargos P; Merlin C; Cantarel C; Cazeau AL
    Clin Nucl Med; 2022 Aug; 47(8):e529-e539. PubMed ID: 35543633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.